Despite Slowing Disease Progression, Amgen's Lung Cancer Studies Show High Liver Toxicity

​​​​​​​Results from two Amgen studies on Lumakras for lung cancer showed its ability to slow disease progression, although combining it with immunotherapy increased the risk for TRAEs.

Related Keywords

Austria ,Vienna ,Wien ,Ib Codebreak ,Al Seib Los Angeles ,Ib Dellphi ,Geralds Falchook ,Hossein Borghaei ,Bobt Li ,Amgen ,Sarah Cannon Research Institute At Health ,Memorial Sloan Kettering Cancer Center ,Los Angeles Times ,Phase Ib Codebreak ,Sarah Cannon Research Institute ,International Association ,Lung Cancer ,Combination Strategies ,Thoracic Medical Oncology ,Fox Chase Cancer Center ,Resume ,Careers ,Espite Slowing Disease Progression ,Mgen 39s Lung Cancer Studies Show High Liver Toxicity ,Iospace ,Advice ,